Sotatercept as an Add-On to Background Therapy in Idiopathic Pulmonary Arterial Hypertension: Insights from a Real-World Cohort
<b>Background</b>: Sotatercept, a first-in-class activin-signaling inhibitor, demonstrated efficacy in pulmonary arterial hypertension (PAH) in the pivotal PULSAR and STELLAR trials. However, whether these benefits and the drug’s distinct safety profile translate to routine clinical practice in the...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2026-05-01
|
| Seria: | Pharmaceuticals |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/1424-8247/19/5/760 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|